secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2022-06-16T23:59:59+00:00
Accession:  0001558370-22-010062
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics promotes Martin Huber to President; appoints Robert Ross to Board
--------------------------------------------------------------------------------

- Martin Huber promoted to President, continues as head of R&D; new employment agreement with $500k base salary and 50% target bonus.
- Huber granted option to purchase 20,000 shares of common stock, vesting over 4 years in equal monthly installments.
- Robert Ross, M.D., appointed to Board as Class II director effective June 15, 2022; also joins Compensation Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/0001558370-22-010062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/xlo-20220615x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-010062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer